How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $25.41 at the start of the year. Since then, BCAX stock has increased by 1.3% and is now trading at $25.73. View the best growth stocks for 2024 here .

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

When does the company's quiet period expire?

Bicara Therapeutics' quiet period expires on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its initial public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Notice: This company recently went public with an IPO on Friday, September 13th 2024. They issued 17,500,000 shares at $18.00 per share. We will continue to update data for BCAX as it becomes available.

NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

$25.30

-0.43 (-1.67%)

(As of 11:44 AM ET)

Compare

Get Bicara Therapeutics alerts:

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Advanced Chart

Get Bicara Therapeutics alerts:

Key Stats

Today's Range: $24.49
▼
$26.11
50-Day Range: N/A
52-Week Range: $21.05
▼
$27.94
Volume: 190,383 shs
Average Volume: 424,446 shs
Market Capitalization: N/A
P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A
Consensus Rating: N/A

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

BCAX Stock News Headlines

Insider Buying: Bicara Therapeutics Inc. (NASDAQ:BCAX) Director Buys 1,833,000 Shares of Stock

September 19 at 8:06 AM | insidertrades.com

Insider Buying: Bicara Therapeutics Inc. (NASDAQ:BCAX) Major Shareholder Purchases 70,000 Shares of Stock

September 18 at 5:22 AM | insidertrades.com

Here comes the May Shockwave

Now that the Fed has spoken, it’s sure to create a May Shockwave! Now's your best chance to trade this historic event using the method that has seen Doubles, Even Triples within just a few days! You see, while most folks will be paying $500… $1,000… or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options in a volatile market. You see, by entering on certain predetermined dates, we have been able to watch as these $0.25 Cent Trades doubled, even tripled in what feels like no time.

September 19, 2024 | DTI (Ad)

Bicara Therapeutics Inc. (NASDAQ:BCAX) Director Ra Capital Management, L.P. Buys 1,833,000 Shares of Stock

September 19 at 8:17 AM | americanbankingnews.com

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

September 16 at 4:01 PM | globenewswire.com

See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

: Bicara Therapeutics' stock was trading at $25.41 at the start of the year. Since then, BCAX stock has increased by 1.3% and is now trading at $25.73.
View the best growth stocks for 2024 here.
: Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.
: Bicara Therapeutics' quiet period expires on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its initial public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
: Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.